Media Coverage

Media Coverage

Stifel’s weekly biopharma update, with data partly compiled by DealForma, highlights industry uncertainty from U.S. Election volatility, steady IPO activity, subdued M&A, and promising obesity drug developments, with new research linking sugar addiction to obesity management. Check out Stifel’s report.

Stifel’s weekly biopharma update covers biotech’s strong 2024 performance, Starboard Value’s activist move on Pfizer, and China’s shifting biotech sector, with data partly compiled by DealForma, plus insights on M&A trends and macroeconomic factors. Check out Stifel’s report.

In Q3 2024, despite mixed indicators for biotech business activity, DealForma’s numbers show that the industry is on track to surpass 2023’s deal totals, though a strong finish in Q4 will be crucial for exceeding last year’s licensing upfronts. Check out Endpoints report.

Stifel’s weekly biopharma update, using data from DealForma, provides an update on the biopharma market for the week of October 7, 2024, discussing strong U.S. jobs data, geopolitical tensions, market volatility, a China stimulus, trends in biotech stocks, capital raising activities, and M&A developments ahead of the U.S. presidential election. Check out Stifel’s report.

BioPharma Dive’s report, leveraging DealForma’s data, uncovers a steep decline in investment for cell and gene therapy developers, attributed to manufacturing and drug delivery challenges, as investors increasingly favor biotechnology companies with more defined development paths. Check out Biopharma Dive’s report.

Stifel’s report, utilizing DealForma’s data, outlines the recent market turbulence, focusing on the sharp declines in tech and biotech stocks due to changes in Japanese interest rates and the resulting impact on investors, while also addressing the potential effects of upcoming political events on the biotech sector. Explore Stifel’s research.

The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less, primarily due to tighter regulatory scrutiny and a smaller pool of large-scale acquisition targets. Check out WSJ’s article.

Nature’s report explores the current state of biotech financing, detailing robust mergers and acquisitions activity and significant private funding rounds, contrasted with difficult public markets and selective venture capital investments, using data from DealForma. Check out Nature’s research.

Stifel’s Mid-2024 Halftime Report, packed with DealForma data, on the biotech market highlights the mixed investor sentiment, strong mid-sized M&A activity, improving inflation, and a predicted robust but bumpy market recovery for the rest of the year. Explore Stifel’s research.

Stifel’s latest update, partly using DealForma data, reviews recent data and updates on the rapidly advancing obesity pharmaceutical market, including insights from the American Diabetes Association and upcoming EASD abstracts. Explore Stifel’s research.

Stifel’s latest update, using DealForma data, reports key oncology pharma market trends, including substantial ASCO conference activity, game-changing therapies, and rising cancer drug spending. Explore the full oncology update.

Stifel’s latest update, using DealForma data, reports key biopharma market events. Highlights include hawkish Fed impacts on biotech stocks, Biogen’s $1.15B HI-Bio acquisition, and $1.7B in follow-on offerings. Checkout the Stifel story.

All of this by stage, disease indication, modality, target…

+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures